116 related articles for article (PubMed ID: 36824887)
1. Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas.
Li J; Chin CR; Ying HY; Meydan C; Teater MR; Xia M; Farinha P; Takata K; Chu CS; Rivas MA; Chadburn A; Steidl C; Scott DW; Roeder RG; Mason CE; Béguelin W; Melnick AM
bioRxiv; 2023 Feb; ():. PubMed ID: 36824887
[TBL] [Abstract][Full Text] [Related]
2. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.
Li J; Chin CR; Ying HY; Meydan C; Teater MR; Xia M; Farinha P; Takata K; Chu CS; Jiang Y; Eagles J; Passerini V; Tang Z; Rivas MA; Weigert O; Pugh TJ; Chadburn A; Steidl C; Scott DW; Roeder RG; Mason CE; Zappasodi R; Béguelin W; Melnick AM
Nat Commun; 2024 Apr; 15(1):2879. PubMed ID: 38570506
[TBL] [Abstract][Full Text] [Related]
3. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
4. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
5. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
[No Abstract] [Full Text] [Related]
6. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
Serganova I; Chakraborty S; Yamshon S; Isshiki Y; Bucktrout R; Melnick A; Béguelin W; Zappasodi R
Front Cell Dev Biol; 2021; 9():805195. PubMed ID: 35071240
[TBL] [Abstract][Full Text] [Related]
9. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.
Kim HJ; Moon SJ; Hong S; Won HH; Kim JH
Nucleic Acids Res; 2022 Aug; 50(14):7873-7888. PubMed ID: 35801925
[TBL] [Abstract][Full Text] [Related]
10. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Zhang J; Dominguez-Sola D; Hussein S; Lee JE; Holmes AB; Bansal M; Vlasevska S; Mo T; Tang H; Basso K; Ge K; Dalla-Favera R; Pasqualucci L
Nat Med; 2015 Oct; 21(10):1190-8. PubMed ID: 26366712
[TBL] [Abstract][Full Text] [Related]
11. Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.
Höpken UE
Cancer Discov; 2017 Jan; 7(1):14-16. PubMed ID: 28062671
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
Zhang X; Wang Y; Chiang HC; Hsieh YP; Lu C; Park BH; Jatoi I; Jin VX; Hu Y; Li R
Breast Cancer Res; 2019 Apr; 21(1):51. PubMed ID: 30995943
[TBL] [Abstract][Full Text] [Related]
13. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
14. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.
Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A
Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328
[TBL] [Abstract][Full Text] [Related]
15. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
16. KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis.
Lin-Shiao E; Lan Y; Coradin M; Anderson A; Donahue G; Simpson CL; Sen P; Saffie R; Busino L; Garcia BA; Berger SL; Capell BC
Genes Dev; 2018 Jan; 32(2):181-193. PubMed ID: 29440247
[TBL] [Abstract][Full Text] [Related]
17. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of lysine demethylation and oxidative phosphorylation.
Dhar SS; Brown C; Rizvi A; Reed L; Kotla S; Zod C; Abraham J; Abe JI; Rajaram V; Chen K; Lee M
bioRxiv; 2023 Nov; ():. PubMed ID: 37961118
[TBL] [Abstract][Full Text] [Related]
18. Abnormal Peyer patch development and B-cell gut homing drive IgA deficiency in Kabuki syndrome.
Pilarowski GO; Cazares T; Zhang L; Benjamin JS; Liu K; Jagannathan S; Mousa N; Kasten J; Barski A; Lindsley AW; Bjornsson HT
J Allergy Clin Immunol; 2020 Mar; 145(3):982-992. PubMed ID: 31816409
[TBL] [Abstract][Full Text] [Related]
19. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Lindsley AW; Saal HM; Burrow TA; Hopkin RJ; Shchelochkov O; Khandelwal P; Xie C; Bleesing J; Filipovich L; Risma K; Assa'ad AH; Roehrs PA; Bernstein JA
J Allergy Clin Immunol; 2016 Jan; 137(1):179-187.e10. PubMed ID: 26194542
[TBL] [Abstract][Full Text] [Related]
20. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
